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Background: Radiation-induced lung injury (RILI) is an important dose-limiting toxicity during thoracic radiotherapy.
The purpose of this study is to investigate single photon emission computed tomography (SPECT)
perfusion-weighted functional dose-volume histogram (FDVH) for predicting RILI in non-small cell lung cancer
(NSCLC) patients treated with definitive chemoradiotherapy.
Methods: Fifty-seven locally advanced NSCLC patients receiving chemoradiotherapy were enrolled prospectively.
Patients had treatment scans and dose calculations to provide a standard dose-volume histogram (DVH). Fusion of
SPECT and computed tomography scans provided perfusion-weighted FDVH and associated functional dosimetric
parameters (relative volumes of functional lung receiving more than a threshold dose of 5 – 60 Gy at increments of
5 Gy [FV5 – FV60]). The predictive abilities of FDVH and DVH were calculated and compared based on the area
under receiver operating characteristic (ROC) curve (AUC).
Results: The accumulative incidence of≥ 2 grade RILI was 19.3% with a median follow-up of 12 months. Univariate
analysis showed that the functional (FV5 – FV60) and standard (V5 – V40) parameters were associated with RILI (all
value of p < 0.05). Close correlations between a variety of functional and standard parameters were found. By ROC
curve analysis, functional metrics (AUCs were 0.784 – 0.869) provided similarly (p value 0.233 – 1.000) predictive
outcome to standard metrics (AUCs were 0.695 – 0.902) in lower – median dose level parameters (FV5 – FV40).
However, FDVH seemed to add some predictive value in higher dose level, the best statistical significance for
comparing FV60 with V60 was 0.693 vs. 0.511 (p = 0.055).
Conclusions: Functional metrics are identified as reliable predictors for RILI, however, this observation still needs to
be further verified using a larger sample size.
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Platinum-based chemoradiotherapy represents the current
treatment standard for locally advanced non-small cell
lung cancer (NSCLC). However, treatment success is con-
strained by poor local control and radiation-induced lung
injury (RILI). According to recent data [1-4], clinical symp-
tom RILI (Grade≥2) has been reported to occur in 7.0 –
32.0%, severe RILI (Grade≥3) 2.6 – 18.0%, and the lethal
RILI (Grade 5) 0 – 2.0%, for patients receiving definitive
chemoradiotherapy.
Recently, multiple risk factors associated with the de-
velopment of RILI have been identified in the literatures,
such as dosimetric factors [1,5-20] (typically the mean
lung dose and relative volume of lung receiving more
than a threshold dose), biomarkers [21,22] (interleukin-
6, transforming growth factor-beta, et cetera), single
nucleotide polymorphisms (SNPs) [23-25], and clinical
factors [1,5,6,9,12,14,16,17]. However, for each individual
patient, there are presently no golden standardized fac-
tors for predicting RILI following radiation therapy (RT).
In clinical practice, the dose-volume histogram (DVH)
parameters, such as mean lung dose (MLD) and V20,
are the most commonly used predictors for RILI. How-
ever, these parameters are not ideal due to their limited
predictive ability [26], which is probably because of the
potential interpatient difference related to inherent radi-
ation sensitivity and base-line pulmonary function are
not considered when constructing DVH parameters.
Lind et al. [6] and Nioutsikou et al. [27] considered
functional parameters, that is standard dosimetric fac-
tors plus the pre-RT pulmonary functional information,
could improve the predictive outcome. Previous studies
[28-31] from Netherlands and Duke University have
confirmed regional lung damage, assessed by single pho-
ton emission computed tomography (SPECT) perfusion
combining the three dimensional dose distribution, was
predictive for the overall pulmonary function changes
and possibly for the prediction of RILI. However, this
functional metrics did not add further predictive value
as anticipation, and failed to identify patients group at
relatively high or low risks of RILI prospectively [14].
In order to better identify the functional metrics in
prediction RILI following chemoradiotherapy in NSCLC
patients, present study prospectively recruited a moder-
ate homogenous patient population to further examine
the predictive value of functional metrics.
Methods
Eligibility and patient population
Fifty-seven locally advanced, unresectable NSCLC
patients enrolled in a prospective phase II study from
March 2006 to April 2010 were analyzed. Eligibility cri-
teria included biopsy-proven NSCLC with clinical stage
IIIA and IIIB, no prior chemotherapy or radiotherapy,no concurrent malignancy and no past history of lung
cancer, Karnofsky Performance Status (KPS) scale ≥ 80,
life expectancy > 6 months, patients without severe com-
plications, such as chronic obstructive pulmonary dis-
ease (baseline of forced expiratory volume in 1.0
second < 40% predicted). Of recruited patients, sixteen
(28.1%) were recorded in stage IIIA (N2), this cohort of
patients treated with definitive chemoradiotherapy were
considered surgically unresectable. To minimize poten-
tial confounding factors, only those patients receiving
definitive chemotherapy and three dimensional radio-
therapy were included. Selective lymph nodes irradiation
was never adopted. The protocol was approved by our
institutional review board, and written informed consent
was obtained from patients.
As part of this study, patients had pre-RT assessments
of base-line lung function including symptom assess-
ment, pulmonary function tests (PFTs), and SPECT
(Infinia; GE) lung perfusion imaging. A pretreatment
positron emission tomography/computed tomograpy
(PET/CT; 4 slice Discovery LS; GE) scan was obtained
for cancer staging and treatment planning.
Treatment planning and delivery
Patients were immobilized and underwent dedicated
18F-fluorodeoxyglucose (18F-FDG) PET/CT scanning in
the treatment position. A SPECT scan was acquired after
planning PET/CT acquisition and before RT. With the
99m-technetium (99m-Tc)-labeled macroaggregated al-
bumin (MAA) was injected intravenously. The same
immobilization device was used in both the SPECT scan
and planning PET/CT scan. The reconstruction and cor-
egistration of images were performed as previously
described [28-31]. The 18F-FDG PET/CT image was
used to delineate the gross tumor volume (GTV) follow-
ing the International Commission on Radiological Units
recommendations, including the primary disease plus
any involved regional lymph nodes as determined by size
on the CT scan to be ≥ 1 cm or FDG-avid lymph nodes,
regardless of their anatomic size. Before commencing
the visual contouring, a diagnostically adequate window
for image display was adjusted with the assistance of our
nuclear medicine physician. The planning target volume
(PTV) was considered to include the GTV plus a 10- to
15-mm margin. Ninety-five percent isodose line encom-
passed the PTV. Normal tissues (esophagus, spinal cord,
heart, and normal lung) were contoured as usual. In
particular, functional lung (FL) was weighted by 99m-
Tc-MAA SPECT lung perfusion with a threshold of
30% of the maximum radioactivity [29]. It is assumed
that perfusion is proportional to function [31]. We deli-
neated the regional well-perfused lung contours as FL.
Based on these functional information, PET/CT/
SPECT-guided radiotherapy planning was optimized
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ation Oncology Systems, Milpitas, CA). Generally, we
preferred to three dimensional conformal radiotherapy
(3D CRT), however, because of complicated target the
intensity-modulated radiotherapy (IMRT) technique was
also performed some times. For 3D CRT, four or five
beams were consistently employed in the treatment
plans, typically anterior-posterior beams in combination
with oblique beams. In IMRT plans, five to seven beam
angles were usually employed for dose optimization.
During the optimization, beem angles were guided by
perfusion image in order to reduce dose distribution in
FL as soon as possible. Dose calculations were per-
formed using Pinnacle3 version 7.6c (ADAC, Milpitas,
CA) with tissue heterogeneity correction. Planning ob-
jective for total lung V20 limited to 37%. The treatment
plans were reviewed by peers and delivered using 6 MV
beams on linear accelerators. All plans adopted with
late-course accelerated hyperfractionated radiotherapy
(LCAHRT): the first phase was implemented with the
conventional fractionated irradiation. This PTV was
defined as receiving 40.0 Gy in total, 2.0 Gy per fraction,
five fractions a week. In the second phase, accelerated
hyperfractionated radiation was employed. The dose was
delivered at 1.4 Gy per fraction, twice daily with a mini-
mum interval of 6 hours, 10 fractions a week to 19.6 –
28.0 Gy in 14 – 20 fractions. The total dose delivered of
the two-phase irradiation would be 59.6 – 68.0 Gy/34 –
40 fractions in 5.4 – 6.0 weeks. All patients received 2 –
4 cycles of concurrent or sequential chemotherapy with
cisplatin-based (25.0 mg/m2× 3 days) regimens. The
chemotherapy regimens used in this study were known
to possess similar toxicity and effectiveness for treatment
of locally advanced NSCLC [32].
Standard dose-volume histogram
The DVH was calculated based on the absolute total
dose without adjustments for fraction size or overall
treatment time. Normal lung was defined as the total
lung excluding GTV, trachea, and main bronchi. DVH
parameters for normal lung were computed from the 3D
dose distributions and were exported from treatment
plans. The percentage of lung volume that received more
than a threshold dose of radiation were calculated,
where the values of threshold dose ranged from 5 to
60 Gy at increments of 5 Gy (V5 – V60).
Functional dose-volume histogram
The 3D SPECT data were transferred electronically from
Nuclear Medicine Center to Radiation Oncology via an
internal network. Software in PLUNC (X Fusion) was
used to visually superimpose the SPECT images with
pre-RT lung contours [14]. After a SPECT scan was ad-
equately registered with the CT data set, the SPECTimage was resampled by tri-linear interpolation to match
the spatial sampling of the CT data set. The entire 3D
RT dose distributions were overlaid on to the SPECT
scan. The percentage of SPECT counts in each dose bin
was used to generate a “dose SPECT-count histogram”.
As it is assumed that perfusion is proportional to func-
tion [31], this histogram is termed a functional dose-
volume histogram (FDVH) [6,14,27,30]. From the
FDVH, the percent of FL receiving from 5 to 60 Gy at
increments of 5 Gy were obtained (FV5 – FV60). The
adjustment of the dose to the biologically equivalent
dose by conventional fractionation size at 2 Gy was not
carried out.
Follow-up and RILI evaluation
The clinical evaluation of patients was performed weekly
during the course of RT. Follow-up examinations were
performed at 1, 3, 6, 9,12 months, and then 6-month
intervals after completion of RT. Pre-RT assessments of
lung function include symptom assessment, PFTs,
SPECT lung perfusion, as well as a whole body PET/CT
scan. Spiral CT-scans of the chest were performed at the
end of treatment, and at every follow-up examination to
monitor morphological changes in lung structure with
respect to RILI. In our analysis, the RILI grade was
defined according to the National Cancer Institute
Common Toxicity Criteria, version 3.0. [33]. The de-
velopment of RILI was considered as a binary variable:
“no-RILI” (Grade ≤ 1) and “RILI” (Grade ≥ 2).
Statistical analysis
Differences of functional and standard dosimetric para-
meters between patients with and without RILI were
compared by independent sample t test. Univariate
(Chi-square) analysis was used to evaluate the impact of
clinical factors, functional and standard dosimetric para-
meters on the development of RILI. The relationship be-
tween functional and standard factors was testing with
Pearson correlation r. Receiver operating characteristic
(ROC) curves were used to identify the reference thresh-
old of potential predictors and to assess their predict-
ability of the parameters. A higher area under the ROC
curve (AUC) indicates a more powerful predictor. The
AUCs for functional and standard dosimetric factors
were used to statistically test for difference between
them. All statistical tests were two-tailed and were per-
formed using statistical software programs SPSS V.16.0.
A p value of <0.05 was considered significant.
Results
Patient, tumor, and treatment characteristics
The characteristics of patients were summarized in
Table 1. The median age was 68 years (range 34 –
71 years). Of the 57 patients, 48 (84.2%) were male and
Table 1 Patient, tumor, and treatment characteristics,
and association with radiation-induced lung injury
Characteristic No. of patients (%) p value
Gender 0.380
Male: Female 48 (84.2): 9 (15.8)
Age (y) 0.750
≥ 60: < 60 36 (63.2): 21 (36.8)
Karnofsky Performance Status 0.470
80: >80 13 (22.8): 44 (77.2)
Histopathology -
Squamous cell carcinoma 28 (49.1)
Adenocarcinoma 20 (35.1)
Large cell carcinoma 3 (5.3)
NSCLC, not otherwise specified 6 (10.5)
Clinical stage 1.000
IIIA: IIIB 19 (33.3): 38 (66.7)
Smoking history 0.702
No: Yes 12 (21.1): 45 (78.9)
Chemotherapy 0.301
Concurrent: Sequential 17 (29.8): 40 (70.2)
Primary tumor location 0.087
Upper: Middle and lower lobe 25 (43.9): 32 (56.1)
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and 38 (66.7%) had stage IIIB. Seventy-nine percent of
patients had a history of smoking. The median baseline
forced expiratory volume in 1.0 sec was 2.08 liters (range
0.62 – 3.59 liters).Figure 1 Comparison for mean value of functional and standard dosi
radiation-induced lung injury (RILI). Error bar represents with 1SD, asteriFor this limited patient population, there was no sig-
nificant difference in the distribution of clinical para-
meters (gender, age, KPS, smoking history) between the
two groups of patients with and without RILI. Moreover,
no tumor-related (tumor location, clinical stage) or
treatment-related factor (chemotherapy) was found dif-
ference between “RILI” and “no-RILI” groups (all value
of p > 0.05).
Treatment toxicity
Of the 57 patients analyzed, 46 (80.7%) developed grade
0 – 1 RILI, eighty percent of whom were asymptomatic
but presented in focal or minimal fibrosis on chest CT
images during the follow-up. Seven (12.3%) patients
experienced grade 2 RILI, and 3 (5.3%) grade 3. One fe-
male patient died of grade 5 RILI after treatment. The
accumulative incidence of grade 2 or worse RILI was
19.3% with a median follow-up of 12 months. In patients
with RILI, RILI was accompanied by worsening of re-
spiratory symptoms with deterioration of lung function
parameters and radiological changes in chest CT-scans.
Dose-volumetric parameters
There were significant differences of functional para-
meters FV5 – FV50 at increments of 5 Gy between
patients with and without RILI (p value 0.001 – 0.041),
similar results were also found in standard parameters
from V5 to V40 (p value 0.001 – 0.040) (Figure 1). By
univariate analysis, we found a variety of FDVH (FV5 –
FV60) and standard DVH (V5 – V40) parameters were
statistically significant (p < 0.05) association with RILI,
and the numerical findings were displayed in Table 2.metric parameters between patients with and without
sk represents with statistically significant difference.
Figure 2 Pearson correlation coefficient between functional
and standard dosimetric parameters.
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meters (Figure 2), we did not perform multivariate ana-
lysis. However, we further tested the predictability for
these potential predictors using ROC curve. Figure 3
demonstrated the standard DVH as predictors for RILI.
Combining with numerical findings, we confirmed V5 –
V35 were significantly predictive for RILI (p < 0.05),
AUCs ranged from 0.729 (95% confidence interval [CI]
0.541 – 0.918, p = 0.026) to 0.902 (95% CI 0.813 – 0.992,
p = 0.001), furthermore, V40 was observed a borderline
significant predictor with a predictive ability of 0.695Table 2 Univariate analysis of functional and standard
dosimetric parameters association with radiation-induced
lung injury (RILI)
Parameters aCut-off value RILI rate (%) p value
FV5 / V5 0.80 / 0.70 b5.3: c47.4 / b5.4: c45.0 0.001 / 0.001
FV10 / V10 0.45 / 0.56 5.4: 45.0 / 5.1: 50.0 0.001 / 0.001
FV15 / V15 0.40 / 0.40 2.9: 43.5 / 0.0: 39.3 0.001 / 0.001
FV20 / V20 0.30 / 0.32 5.6: 42.9 / 3.2: 38.5 0.001 / 0.001
FV25 / V25 0.28 / 0.26 9.1: 53.8 / 5.9: 39.1 0.001 / 0.004
FV30 / V30 0.21 / 0.21 7.7: 44.4 / 8.6: 36.4 0.002 / 0.015
FV35 / V35 0.15 / 0.17 7.3: 50.0 / 7.9: 42.1 0.001 / 0.004
FV40 / V40 0.14 / 0.17 7.1: 53.3 / 7.1: 31.0 0.001 / 0.041
FV45 / V45 0.11 / 0.13 7.1: 53.3 / 9.7: 30.8 0.001 / 0.089
FV50 / V50 0.07 / 0.11 7.1: 53.3 / 12.8: 37.5 0.001 / 0.061
FV55 / V55 0.06 / 0.08 9.5: 50.0 / 15.8: 31.3 0.003 / 0.270
FV60 / V60 0.04 / 0.03 10.0: 43.8 / 15.0:22.6 0.008 / 0.721
Note: functional dosimetric parameters associated with RILI were typed with
bold.
a Cut-off value was optimized by receiver operating characteristic curve.
b RILI rate calculated when Vx < cut-off value.
c RILI rate calculated when Vx ≥ cut-off value.(95% CI 0.488 – 0.902, p = 0.058). However, V45 – V60
failed to identify patients who were at risk of developing
RILI (AUCs were 0.511 – 0.656, p > 0.1). Comparing
with standard DVH parameters, functional parameters
provided equally or slightly better predictive outcome.
As indicated in Figure 4, all the ROC curves of func-
tional parameters were aboved the predictive reference
line. Functional parameters observed in present study
(FV5 – FV60) could successfully distinguish patients at
risk for RILI from current cohort of patients. In order to
better ascertain their prognostic value to predict RILI
comparing with standard DVH parameters, we com-
pared predictability based on the area beneath ROC
curve. For parameters in lower and median dose level (5
– 40 Gy), the FDVH yielded similar predictability to
standard DVH, the difference of AUCs was less than 0.1
(p value 0.233 – 1.000). As for parameters in higher dose
level (40 – 60 Gy), the functional metrics generally pro-
vided better predictability to their counterparts, the dif-
ference between ROC areas even reached to 0.2 at 60 Gy
dose level (0.693 vs. 0.511, p = 0.055) (Table 3).
Discussion
At present, the mechanisms of RILI have not yet been
fully understood. Current studies suggest that many fac-
tors, including dosimetry [1,5-20], cytokines [21,22],
SNPs [23-25], and clinical factors (such as tumor location
[5], pre-RT lung function [6,14], age [9], smoking history
[16], gender [17], chemotherapy [1,17] and radiotherapy
technique [20], et cetera), contribute to the risk of devel-
opment of RILI, nonetheless, the occurrence of RILI
remains unpredictable. Therefore, more reliable predic-
tors or methods in identifying individuals at a high risk
of developing RILI are most desirable for early treatment
modifications in order to avoid serious complications.
In present study, we developed the SPECT weighted
functional dosimetric parameters to attempt to predict
lung toxitity induced by LCAHRT. The present report
demonstrated that a variety of parameters including
standard (V5 – V40) and functional (FV5 – FV60) para-
meters were significantly associated with RILI, and the
results were in accordance with previous studies
[8,9,11,12,15-18,22]. For example, in the study by Dang
et al. [17], they considered that lung was a parallel organ
and so the functional subunits were connected in paral-
lel. Although a large volume of lung with a low dose of
radiation would harm the functions of several subunits
[11-13,15], the much higher dose of radiation given to a
small lung volume might enlarge the impairment pro-
gressively and finally lead to the impairment of the
whole-lung function [18,19]. It is believed that the fac-
tors of dosage and lung volume are equally important to
RILI morbidity, which cannot be determined by a single
DVH parameter [8,16,17,19]. Due to the colinearity
Figure 3 ROC curve analysis for standard metrics as predictors for radiation-induced lung injury.
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and Additional file 1: Table S1) and prior studies
[7,8,12,16,17], we could not induct them into the regres-
sion model simultaneously when the multivariate ana-
lysis was carried out. As reported in Table 2 of this
paper, all the FDVH and most of the DVH parameters
were evidently related to the occurrence of RILI. If any
one of parameters was above a certain value, there might
be a higher risk for development of RILI. Kocak et al.
[14] suggested that the precise dosimetric parameter
selected was not critical as there was a strong correlation
between the different dosimetric parameters as long as
the radiation technique being used is relatively uniform
across patients. Jin et al. [16] also noted very high corre-
lations among relative volumes of lung exposed to vari-
ous dose thresholds, therefore they investigated a
comprehensive list of dosimetrics parameters rather than
an individual dose-volume constraint. The results indi-
cated that if lung DVH met a set of “threshold” con-
straints, i.e., V20 < 25%, V25 < 20%, V35 < 15%, and
V50 < 10%, the incidence of RILI was extremely low, only
2% at 1 year. Until the effects of different dose levels on
lung toxicity were better understood, they proposedFigure 4 ROC curve analysis for functional metrics as predictors for rausing the shape of the DVH curve, rather than a single
point on DVH, to limit incidence of RILI.
SPECT of 99m-Tc-labeled MAA provides a map of the
spatial distribution of lung perfusion, which has been
shown to be proportional to lung function. The SPECT
image directly correlates the concentration of radiola-
beled microspheres to regional blood flow. Perfusion im-
aging is clinically relevant to lung function because
ventilation without perfusion is more common than per-
fusion without ventilation. This functional information
has been used in radiotherapy planning to identify nor-
mal functioning lung tissue when treating lung tumors
using three-dimensional radiation treatment planning. It
is believed that ideal radiation should be delivered in a
manner that minimizes its functional consequences. For
the most part, this goal has been sought by trying to
minimize the volume of computed tomography-defined
lung tissue within the treatment fields. This approach
does not, however, consider possible variations in the
functional competence of different regions of the lung
[27,34]. The same problem arises in the interpretation of
DVH. From the viewpoint of biophysics, DVH para-
meters are constructed to consider both lungs as adiation-induced lung injury.
Table 3 Pairwise comparison of AUCs between functional
and standard dosimetric parameters for predicting
radiation-induced lung injury
Parameters aDBA p value 95% Confidence Interval
Lower Upper
FV5 vs. V5 0.020 0.922 −0.113 0.125
FV10 vs. V10 0.032 0.819 −0.075 0.095
FV15 vs. V15 0.033 0.770 −0.090 0.122
FV20 vs. V20 0.034 1.000 −0.146 0.146
FV25 vs. V25 0.003 0.655 −0.127 0.202
FV30 vs. V30 0.065 0.308 −0.082 0.260
FV35 vs. V35 0.055 0.564 −0.114 0.209
FV40 vs. V40 0.093 0.233 −0.064 0.261
FV45 vs. V45 0.124 0.114 −0.033 0.308
FV50 vs. V50 0.176 0.081 −0.019 0.323
FV55 vs. V55 0.141 0.120 0.029 0.254
FV60 vs. V60 0.182 0.055 −0.004 0.346
Note: AUC area under the receiver operating characteristic curve (ROC).
a DBA: Difference between ROC areas.
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to radiation toxicity is presented in the spatial differ-
ences [27,34]. Furthermore, co-existent lung diseases in
the majority of lung cancer patients result in regional
differences in lung function. Therefore, using the FDVH
may be more meaningful for plan evaluation and is
anticipated to show a better correlation with RILI.
Lind et al. [6] suggested that considered the pre-RT
pulmonary function (PFTs and SPECT lung perfusion
scans) combining with three-dimensional dose distribu-
tion seemed to be best ability to predict outcome. De
Jaeger et al. [30] also reported perfusion weighted dosi-
metric parameters provided a better estimation of lung
functional outcome after high-dose radiotherapy of
NSCLC than pure dose parameters. Kocak et al. [14]
prospectively assessed the dosimetric/functional para-
meters in two groups patients from Duke and the Neth-
erlands Cancer Institute (NKI) for predicting radiation
pneumonitis. In the Duke data, perfusion weighted
parameters (FV20 – FV30) had slightly greater AUCs
than standard parameters (0.54 – 0.55 vs. 0.51 – 0.54),
however, mean perfusion weighted lung dose (MpLD)
had slightly lower AUC than MLD (0.59 vs. 0.62). On
the contrary, in the NKI data, MpLD appeared as the
most significant predictor, better than the nonperfusion
weighted parameter (0.71 vs. 0.61).
In present study, perfusion weighted parameters gen-
erally provided similarly (AUCs were 0.784 – 0.869 for
FDVH vs. 0.695 – 0.902 for DVH) predictive outcome to
nonperfusion weighted parameters in lower and median
dose level. In respect to parameters in higher dose level,
functional metrics appeared to be better than standardmetrics (AUCs were 0.693 – 0.788 for FDVH vs. 0.511 –
0.695 for DVH). There was a borderline statistical sig-
nificance for comparing FV60 with V60 (p = 0.055). As
shown in Figure 4, ROC curve distributions for func-
tional parameters in higher dose level were distinctly
better than standard parameters displayed in Figure 3,
which demonstrated the characteristic of standard para-
meters as predictors for RILI. From these charts, we
found a certain trend that functional metrics improved
the predictive outcome in higher dose level. Therefore,
considering our limited sample size, we presumed that
perfusion weighted functional metrics might be more re-
liable as predictors for RILI comparing with standard
metrics. Moreover, according to report by Nioutsikou
et al. [27], functional metrics might be provide better
predictive outcome in cases with localized perfusion def-
icits, while no added benefit in lung tumors with patchy
perfusion.
Contemplating the present study, several factors may
confine the predictive outcome of using FDVH
metrics. Firstly, in our study, sample size is not large
enough to reveal such a significant difference. Sec-
ondly, we considered a perfusion value of 30% or more
of the maximum radioactivity to be functional and the
remaining regional lung was not [29]. In fact, normal
lung function is similar to a spectrum, the use of a
30% cutoff point creates FL and non-FL, which may
result in losing parts of the ‘non-FL’ information or
underestimating the function in these regions [28].
Furthermore, the optimized cutoff point for creating
FL has not yet been identified, therefore, FDVH para-
meters derived from the best cutoff point might be
more associated with development of RILI. Further
studies focusing on FL definition will help to better
clarify the characteristic of FDVH metrics for predict-
ing RILI. Thirdly, because of perfusion image was ac-
tually used to optimize the radiation plan, this might
lead to a reduced sensitivity with regard to the predict-
ive value of functional metrics. At last, the diagnostic
uncertainty of radiation pneumonitis may be a factor
that makes the prediction of RILI difficult. Pre-existing
lung disease, tumor regrowth/progression, and cardiac
disease that may confound the diagnosis.Conclusions
This prospective study suggests that standard (V5-V40)
and functional (FV5-FV60) parameters are potential pre-
dictors in the identification of patients at risk of RILI. In
general, functional metrics provide similar predictability
to standard metrics, and functional parameters in higher
dose level seem to be more reliable to their counterparts,
however, this observation still needs to be further veri-
fied using a larger sample size.
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